Lyophilized Biologic Formulation Patents: Who Leads, Where Gaps Are 2026
Lyophilized Biologic Formulation Patents: Mapping the Field
Concentration is modest at the top. the five most active assignees hold 19.4% of all 9,460 records, and the ranked ten hold 30.6% — the rest is a long tail. Filings peaked in 2017 at 549 records. The 2021-to-2024 window, the last stretch with complete publication, shows a 37% decline from 494 to 311 records — a real contraction in new claim activity, not an artefact of publication lag.
- 1TAKEDA PHARMA CO LTD5.5%
- 2BRISTOL MYERS SQUIBB CO4.3%
- 3NOVARTIS AG3.8%
- 4GENENTECH INC3.2%
- 5F HOFFMANN LA ROCHE & CO AG2.6%
See the full lyophilized biologic formulation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this patent landscape
How concentrated is the lyophilized biologic formulation patent landscape?
It is only moderately concentrated. The five most active assignees together hold 19.4% of the 9,460 records in scope, and the ten most active hold 30.6%. That leaves the majority of records spread across a long tail of assignees with only a handful of filings each, so the field is not controlled by one or two dominant players. A new entrant should expect to negotiate around several mid-sized portfolios rather than a single gatekeeper.
Is filing activity in lyophilized biologic formulation growing or shrinking?
Filing peaked in 2017 at 549 records and has since pulled back. Looking at the most recent complete years, 2021 to 2024, filings fell 37%, from 494 to 311. Note that 2025 and later years will look artificially low in any raw count because publication typically lags filing by around 18 months, so those years should not yet be read as a continuation of the decline.
What patent classes dominate lyophilized biologic formulation filings?
A61K, medicinal preparations, appears on 87.9% of the 9,460 records, making it by far the dominant class. C07K (peptides and proteins) and A61P (therapeutic activity of compounds) each appear on roughly a third of records. Classes tied to process analytics and testing, such as G01N, appear on under 3% of records, indicating that most claim activity protects formulation composition rather than the measurement methods used to validate a cycle.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.